NEW YORK — Genosity said on Wednesday that it has signed an agreement to develop a molecular diagnostic for use in selecting patients for a clinical trial of a dry age-related macular degeneration (AMD) drug candidate under development by Gemini Therapeutics.
Gemini's drug, called GEM103, is designed for dry AMD in patients with disease-associated complement factor H (CFH) loss-of-function gene variants.